Cardiol Therapeutics Inc. (CRDL) 股票分析

公司概述

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company dedicated to the development of anti-fibrotic and anti-inflammatory therapies designed specifically for the treatment of heart diseases. The company functions within the Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical compounds rather than mass-market generic drugs. According to available data, the company holds a market capitalization of $154.12M, while annual revenue figures are not reported (N/A) and employee count data is unavailable (N/A). These valuation metrics suggest the company is a micro-cap entity with limited revenue history, positioning it as a high-risk, high-potential biotechnology firm whose value is derived primarily from its clinical pipeline rather than established commercial sales streams.

财务健康

The company reported a net income of $-33,818,872 and an EBITDA of $-34,278,296, while revenue figures are not applicable (N/A) in the provided data. The significant gap between the reported net income and EBITDA reveals a substantial cost structure burden, where non-operating expenses or interest costs consume nearly the entire earnings before interest and taxes, indicating that the company is not yet profitable and is burning cash to fund its clinical operations. Free cash flow stands at $-13,026,343, which signifies that the company is in a cash-consumptive phase typical of clinical-stage biotech firms, yet it maintains a cash reserve of $21.42M to support its ongoing research and development activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet generated commercial revenue sufficient to calculate meaningful margins or that current financial reporting treats these figures as negligible due to lack of sales. In terms of leverage, the company holds $21.42M in cash against a debt level of $125,523, resulting in a conservative balance sheet supported by a debt-to-equity ratio of 0.70, suggesting that while debt exists, it is heavily offset by liquid assets. The current ratio is reported at 4.16, which indicates a strong position in short-term liquidity, meaning the company possesses more than four times the current assets required to cover its current liabilities. Furthermore, the Return on Equity is -158.8% and the Return on Assets is -77.3%, metrics that reveal that management is currently unable to generate positive returns on the capital invested by shareholders or held in assets, reflecting the early-stage nature of the business model.

估值评估

Trailing P/E and Forward P/E metrics are reported as N/A and -8.11 respectively, where the negative forward P/E implies that the market is pricing in a period of continued negative earnings rather than a traditional growth trajectory based on current profitability. The Price to Book ratio is 17.60, which indicates that the market is valuing the company at a significant premium over its book value, a common phenomenon for clinical-stage biotechs where the asset value is heavily weighted toward intellectual property and pipeline potential rather than tangible assets. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-3.88) suggest that traditional sales-based multiples are not applicable, while the negative EV/EBITDA reinforces the fact that the company is currently unprofitable and its enterprise value is driven by future clinical success probabilities. The 52-week high is $1.59 and the 52-week low is $0.80, and without a specific current share price provided in the facts, the trading range indicates a volatility of approximately 58% between these two points, reflecting the speculative nature of the stock. The Beta is 0.43, which explains that the stock price exhibits lower volatility relative to the broader market, moving less than half as much as the market index during typical periods of fluctuation.

Growth & Income

Revenue growth and earnings growth rates are both listed as N/A, which precludes any analysis of whether earnings are growing faster or slower than revenue as the company has not yet established a revenue base to measure growth against. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that the company reinvests all available earnings and cash reserves directly into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete reliance on capital raising and cash reserves to fund operations, with no current income generation to support shareholder returns or historical growth metrics.